曹鹏;邱萌

• 1:四川大学华西医院腹部肿瘤科，四川 成都 610041

摘要(Abstract)：

绝大多数结直肠癌属于微卫星稳定型，免疫微环境表现为“冷肿瘤”，基本对以免疫检查点抑制剂为主的单一免疫治疗不敏感。目前临床研究方向和热点主要聚焦于两个方面：（1）将免疫治疗与传统化疗、靶向或局部治疗联合应用，以期调节微卫星稳定型结直肠癌的免疫微环境，尝试将“冷肿瘤”转变为“热肿瘤”，从而提高对免疫治疗的有效性；（2）筛选潜在有意义的免疫治疗疗效预测标志物和临床特征，富集微卫星稳定型结直肠癌中免疫治疗获益的人群。本文将对微卫星稳定型结直肠癌免疫治疗研究现状和热点问题进行全面梳理和评述。

关键词(KeyWords)： 结直肠癌;免疫治疗;微卫星稳定型;错配修复缺陷

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 曹鹏;邱萌

DOI: 10.13267/j.cnki.syzlzz.2022.017

参考文献(References)：

• [1] Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer:rationale, challenges and potential[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6):361-375.
  [2] Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26):2509-2520.
  [3] Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics:opportunities and challenges[J]. Nat Rev Clin Oncol, 2018, 15(5):325-340.
  [4] Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer:an open-label, dose-escalation, and dose-expansion phase Ⅰb trial (REGONIVO, EPOC1603)[J]. J Clin Oncol, 2020, 38(18):2053-2061.
  [5] Fakih M, Raghav KPS, Chang DZ, et al. Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC)[J]. J Clin Oncol, 2021, 39(15_suppl):3560.
  [6] Cousin S, Bellera CA, Guégan JP, et al. REGOMUNE:a phase Ⅱ study of regorafenib plus avelumab in solid tumors-Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort[J]. J Clin Oncol, 2020, 38(15_suppl):4019.
  [7] Wang F, He MM, Yao YC, et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer:a phase Ⅰb/Ⅱ clinical trial and gut microbiome analysis[J]. Cell Rep Med, 2021, 2(9):100383.
  [8] Gou MM, Yan H, Liu Tie E, et al. Fruquintinib combination with sintilimab in refractory metastatic colorectal cancer patients in China[J]. J Clin Oncol, 2020, 38(15_suppl):4028.
  [9] Guo Y, Zhang WJ, Ying JE, et al. Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer[J]. J Clin Oncol, 2021, 39(15_suppl):2514.
  [10] Gomez-Roca CA, Yanez E, Im SA, et al. LEAP-005:A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors-Results from the colorectal cancer cohort[J]. J Clin Oncol, 2021, 39(15_suppl):3564.
  [11] Mettu NB, Twohy E, Ou FS, et al. BACCI:a phase Ⅱ randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC):an ACCRU network study[J]. Ann Oncol, 2019, 30:v203.
  [12] Grothey A, Tabernero J, Arnold D, et al. Fluoropyrimidine (FP)+bevacizumab (BEV)+atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC):Findings from Cohort 2 of MODUL-a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy[J]. Ann Oncol, 2018, 29:LBA19.
  [13] Cremolini C, Rossini D, Antoniotti C, et al. LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients:results of the phase Ⅱ randomized AtezoTRIBE study by GONO[J]. Ann Oncol, 2021, 32:S1294-S1295.
  [14] Arai H, Battaglin F, Wang JY, et al. Molecular insight of regorafenib treatment for colorectal cancer[J]. Cancer Treat Rev, 2019, 81:101912.
  [15] Ferris RL, Lenz HJ, Trotta AM, et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors:Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation[J]. Cancer Treat Rev, 2018, 63:48-60.
  [16] Stein A, Binder M, Goekkurt E, et al. Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC):final results of the phase Ⅱ AVETUX trial (AIOKRK-0216)[J]. J Clin Oncol, 2020, 38(4_suppl):96.
  [17] Martinelli E, Martini G, Troiani T, et al. 397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy:the phase Ⅱ CAVE (cetuximab-avelumab) mCRC study[J]. Ann Oncol, 2020, 31:S409-S410.
  [18] van den Eynde M, Huyghe N, de Cuyper A, et al. Interim analysis of the AVETUXIRI trial:Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC)-A proof of concept, open-label, nonrandomized phase Ⅱ a study[J]. J Clin Oncol, 2021, 39(3_suppl):80.
  [19] Cremolini C, Rossini D, Dell'Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan:a phase 2 single-arm clinical trial[J]. JAMA Oncol, 2019, 5(3):343-350.
  [20] Lee MS,Loehrer PJ,Imanirad I, et al. Phase Ⅱ study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC)[J]. J Clin Oncol, 2021, 39(3_suppl):7.
  [21] Ebert PJR, Cheung J, Yang YG, et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade[J]. Immunity, 2016, 44(3):609-621.
  [22] Bendell JC, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)[J]. J Clin Oncol, 2016, 34(15_suppl):3502.
  [23] Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370):a multicentre, open-label, phase 3, randomised, controlled trial[J]. Lancet Oncol, 2019, 20(6):849-861.
  [24] Corcoran R, Giannakis M, Allen J, et al. SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAF^V600E colorectal cancer patients[J]. Ann Oncol, 2020, 31:S226-S227.
  [25] Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, et al. Paradigms on immunotherapy combinations with chemotherapy[J]. Cancer Discov, 2021, 11(6):1353-1367.
  [26] Kim R, Chaves J, Kavan P, et al. 493P Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC):updated results from KEYNOTE-651 cohorts B and D[J]. Ann Oncol, 2020, 31:S450.
  [27] Ghiringhelli F, Chibaudel B, Taieb J, et al. Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC):Results of the first intermediate analysis of the phase Ⅰb/Ⅱ MEDETREME trial[J]. J Clin Oncol, 2020, 38(15_suppl):3006.
  [28] Ree AH, Hamre H, Kersten C, et al. Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC):Initial results from the randomized METIMMOX study[J]. J Clin Oncol, 2021, 39(15_suppl):3556.
  [29] Pietrantonio F, Morano F, Lonardi S, et al. MAYA trial:Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)[J]. Ann Oncol, 2021, 32(5_suppl):S530-S582.
  [30] Chen EX, Jonker DJ, Loree JM, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer:the Canadian cancer trials group CO.26 study[J]. JAMA Oncol, 2020, 6(6):831-838.
  [31] Chen E, Jonker D, Kennecke H, et al. CCTG CO.26:Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase Ⅱ trial of durvaluma b (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC)[J]. J Clin Oncol, 2019, 37(15_suppl):3512.
  [32] Garralda E, Sukari A, Lakhani NJ, et al. A phase 1 firstin-human study of the anti-LAG-3 antibody MK4280(favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer[J]. J Clin Oncol, 2021, 39(15_suppl):3584.
  [33] Kim TW, Lee KW, Ahn JB, et al. Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer[J]. J Clin Oncol, 2021, 39(15_suppl):3573.
  [34] Wang YF, Liu ZG, Yuan HF, et al. The reciprocity between radiotherapy and cancer immunotherapy[J]. Clin Cancer Res, 2019, 25(6):1709-1717.
  [35] Qian L, Shen YH, Xie J, et al. Immunomodulatory effects of ablation therapy on tumors:Potentials for combination with immunotherapy[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(1):188385.
  [36] Parikh AJ, Clark JW, Wo JY, et al. A phase Ⅱ study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC)[J]. J Clin Oncol, 2019, 37(15_suppl):3514.
  [37] Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nat Med, 2020, 26(4):566-576.
  [38] Avallone A, Delrio P, Nasti G, et al. Preoperative nivolumab in patients (pts) with locally advanced colon cancer (T3 or T4):a window-of-opportunity study (NICOLE)[J]. Ann Oncol, 2018, 29:viii203.
  [39] 刘爽,姜婷,陈功,等.局部进展期直肠癌治疗模式新进展[J].实用肿瘤杂志, 2021, 36(1):10-17.
  [40] Yuki S, Bando H, Tsukada Y, et al. Short-term results of VOLTAGE-A:nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable andmicrosatellite instability-high locally advanced rectal cancer (EPOC 1504)[J]. J Clin Oncol, 2020,38(15_suppl):4100.
  [41] Salvatore L, Bensi M, Corallo S, et al. Phase Ⅱ study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC):the AVANA study[J]. J Clin Oncol, 2021, 39(15_suppl):3511.
  [42] George TJ, Yothers G, Theodore S, et al. NRG-GI002:A phase Ⅱ clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)-First experimental arm (EA) initial results[J]. J Clin Oncol, 2019, 37(15_suppl):3505.
  [43] Dutt S, Ahmed MM, Loo BW Jr, et al. Novel radiation therapy paradigms and immunomodulation:Heresies and hope[J]. Semin Radiat Oncol, 2020, 30(2):194-200.
  [44] Lin Z, Cai M, Zhang P, et al. Phase Ⅱ, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer[J]. J Immunother Cancer, 2021, 9(11):e003554.
  [45] Wang F, Zhao Q, Wang YN, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types[J]. JAMA Oncol, 2019, 5(10):1504-1506.
  [46] Garmezy B, Gheeya JS, Zin Thein K, et al. Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy[J]. J Clin Oncol,2020, 38(15_suppl):3008.
  [47] Fabrizio DA, George TJ Jr, Dunne RF, et al. Beyond microsatellite testing:assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition[J]. J Gastrointest Oncol, 2018, 9(4):610-617.
  [48] Yu JL, Green MD, Li SS, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination[J]. Nat Med, 2021, 27(1):152-164.
  [49] Ho WW, Gomes-Santos IL, Aoki S, et al. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy[J]. Proc Natl Acad Sci USA, 2021, 118(45):e2105323118.
  [50] Huh JW, Lee JH, Kim HR. Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer[J]. Arch Surg, 2012, 147(4):366-372.
  [51] Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer:a prognostic and accuracy study[J]. Lancet, 2018, 391(10135):2128-2139.
  [52] Overman MJ, Lonardi S, Leone F, et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer:update from CheckMate 142[J]. J Clin Oncol, 2017, 35(4_suppl):519.